Rx-360 warns Pharmas of potential L-Arginine shortage

Related tags Amino acid

Rx-360 warns Pharmas of potential L-Arginine shortage
Pharma supply chain consortium Rx-360 has advised drugmakers to check their L-Arginine stocks, warning that a recent surge in demand could limit supplies.

In an alert published yesterday Rx-360 suggested that pharmaceutical manufacturers contact their suppliers, check supply chains for potential vulnerabilities and perform analytical testing on each batch of the amino acid they receive.

The warning follows a report by North Carolina, US-based supplier Doe & Ingalls​’ (D&I) that an increase in demand from the healthcare sector had lengthened L-Arginine production timelines.

Recently, increased demand for sensitive teeth formulations of toothpaste has caused the L-Arginine market to tighten. With this increased demand, we have heard reports of backorders lasting from Q2 2012 up to Q1 2013.

D&I added that it is working with partners to fill backorder demand, but also recommended that pharmaceutical manufacturers try to forecast their L-Arginine needs for the next two quarters to ensure suppliers are available.

L-Arginine is widely used in drug production – primarily in the manufacture of pharmaceutical intermediates but also – increasingly - as an additive in the manufacturing of biologic drugs to prevent protein aggregation and boost yields.

Related news

Related product

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us